Clinical Trials Logo

Clinical Trial Summary

Prosthetic Joint Infection (PJI) of a Total Hip Replacement (THR) is a disastrous complication of an otherwise extremely successful surgical procedure. It is associated with a burdensome treatment for the patient, significant challenges for the medical team and high costs for society. As more joint replacements are being performed each year, due to an ageing population and lower thresholds for surgery, the number of PJIs is on the rise. Many of these patients will be referred to University Hospitals Leuven as the physicians have extensive experience with this particular pathology and can offer a multidisciplinary and patient-tailored treatment. Many controversies exist in the field of PJI treatment, both with regard to the surgical aspects as well as the antibiotic treatment. Setting up randomized controlled trials to answer these questions has been proven to be very difficult due to large variations in patients, implants, germs, soft and hard tissues, antibiotic resistance patterns, and so on. Also, surgery for PJIs is usually non-elective / semi-urgent and therefore time to include patients into different trials is limited. Therefore the investigators will prospectively collect data on patients with PJI treated at University Hospitals Leuven, starting 01/01/2022, in order to have knowledge of own results and inform patients about chances of success prior to treatment; perform internal audits and quality checks; answer questions in the field of PJI treatment not suitable for RCTs.


Clinical Trial Description

Prosthetic Joint Infection (PJI) of a Total Hip Replacement (THR) is a disastrous complication of an otherwise extremely successful surgical procedure. It is associated with a burdensome treatment for the patient, significant challenges for the medical team and high costs for society. As more joint replacements are being performed each year, due to an ageing population and lower thresholds for surgery, the number of PJIs is on the rise. Many of these patients will be referred to University Hospitals Leuven as the physicians have extensive experience with this particular pathology and can offer a multidisciplinary and patient-tailored treatment. Many controversies exist in the field of PJI treatment, both with regard to the surgical aspects as well as the antibiotic treatment. Setting up randomized controlled trials to answer these questions has been proven to be very difficult due to large variations in patients, implants, germs, soft and hard tissues, antibiotic resistance patterns, and so on. Also, surgery for PJIs is usually non-elective / semi-urgent and therefore time to include patients into different trials is limited. Nevertheless, prospectively collecting data on patients with PJI who are not involved in RCTs can already be helpful. It would allow the investigators to provide the patients with percentages of success of certain interventions based on historical results. At the moment the investigators have to rely on results reported by other groups, who might use different techniques or a facing a different germ spectrum. Furthermore, prospectively collecting data on this cohort of patients, would make it possible for the investigators to do internal audits for quality control. Being able to perform simple checks, for example is every patient discussed in the multi-disciplinary team meeting, or is the hospital switching to targeted antibiotics soon enough, would already add to the quality of the service and could lead to adjustments in the protocols. Also, certain scientific questions, which do not lend themselves to RCTs, such as the rate of success of treatment of PJI caused by rare germs (e.g. fungi) or in a specific population (e.g. octogenarians, transplant patients), could be answered by maintaining a prospective database ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05000723
Study type Observational [Patient Registry]
Source Universitaire Ziekenhuizen KU Leuven
Contact Georges Vles, MD, PhD
Phone 016340888
Email georges.vles@uzleuven.be
Status Recruiting
Phase
Start date July 14, 2022
Completion date December 2099

See also
  Status Clinical Trial Phase
Completed NCT04067843 - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study N/A
Enrolling by invitation NCT05247281 - NGS vs Culture Outcomes for Treatment of PJI N/A
Withdrawn NCT05269121 - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT02801253 - Cohort of Prosthetic Joint Infections
Completed NCT03694925 - Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Completed NCT03721328 - Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation Phase 2
Withdrawn NCT04787250 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT03307109 - Quality of Life in Patients Having a Prosthetic Joint Infection
Recruiting NCT04661345 - Identification of Molecular Marker of Coagulase-negative Staphylococci for the Diagnosis of Prosthetic Joint Infections
Recruiting NCT02805803 - Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection. N/A
Completed NCT02413034 - The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures N/A
Recruiting NCT03784807 - New Strategies for Biofilm Related Infections
Completed NCT04662632 - Abbreviated Protocol for Two-Stage Exchange Phase 2
Not yet recruiting NCT04390607 - Leukocyte Esterase Sensor Test
Recruiting NCT04650607 - Phage Safety Cohort Study
Active, not recruiting NCT04946500 - Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
Recruiting NCT04762706 - Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot. N/A
Withdrawn NCT05269134 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI) Phase 2
Not yet recruiting NCT05239312 - Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
Completed NCT04294862 - Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty Phase 1